Drug Utilization Review Board (DURB) Agenda

October 12, 2023 - 9:00 am

Texas Health and Human Services Commission (HHSC), John H. Winters Building, Public Hearing Room 125, 1st Floor
701 West 51st Street, Austin, TX
78751
United States

This meeting will be webcast. Members of the public may attend the meeting in person at the address above or access a live stream of the meeting at https://texashhsmeetings.org/HHSWebcast. Select the tab for the Winters Live on the date and time for this meeting. Please e-mail Webcasting@hhsc.state.tx.us if you have any problems with the webcasting function.

This meeting will also be conducted via videoconference call in accordance with the requirements of Section 551.127, Government Code. The member of the Board presiding over the meeting will be physically present at the location specified above.

Attendees who would like to provide public comment should see the Public Comment section below.

  1. Call to order
  2. Consideration of July 21, 2023, draft meeting minutes
  3. Public comment and discussion on the July drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Alzheimer’s Agents
    2. Antihistamines, minimally sedating
    3. Calcium Channel Blockers
    4. Cephalosporins and Related Antibiotics
    5. Fluoroquinolones, oral
    6. Glucocorticoids, oral
    7. Immunomodulators, Lupus
    8. Immunosuppressives, oral
    9. Iron, oral
    10. Leukotriene Modifiers
    11. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    12. Ophthalmic Antibiotics
    13. Ophthalmic Antibiotic-steroid combinations
    14. Ophthalmics, anti-inflammatories
    15. Ophthalmics, anti-inflammatory/immunomodulator
    16. Ophthalmics for allergic conjunctivitis
    17. Ophthalmics, glaucoma agents
    18. Otic Antibiotics
    19. Otic Anti-infectives and anesthetics
    20. Penicillins
    21. Progestational Agents
    22. Rosacea Agents, topical
    23. Skeletal Muscle Relaxants
    24. Steroids, topical high
    25. Steroids, topical low
    26. Steroids, topical medium
    27. aa. Steroids, topical very high
    28. bb. Ulcerative Colitis Agents
    29. cc. Uterine Disorder Treatments
  4. Public comment and discussion on the October drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Androgenic Agents, topical
    2. Antibiotics, gastrointestinal (GI)
    3. Antibiotics, topical
    4. Antibiotics, vaginal
    5. Anticonvulsants
    6. Antiemetic/Antivertigo Agents
    7. Antifungals, oral
    8. Antifungals, topical
    9. Antihistamines, first generation
    10. Antiparasitics, topical
    11. Antipsychotics
    12. Antivirals, topical
    13. Bone Resorption Suppression and Related Agents
    14. Colony Stimulating Factors
    15. Epinephrine, self-injected
    16. GI Motility, chronic
    17. Growth Hormone
    18. HIV / AIDS
    19. Hypoglycemics, incretin mimetics/enhancers
    20. Hypoglycemics, insulin and related agents
    21. Hypoglycemics, meglitinides
    22. Hypoglycemics, metformins
    23. Hypoglycemics, sodium-glucose cotransport-2 (SGLT2) inhibitors
    24. Hypoglycemics, thiazolidinediones (TZDs)
    25. Macrolides/Ketolides
    26. Opiate dependence treatments
    27. aa. Tetracyclines
  5. Public comment and discussion on single new drugs to be reviewed for the Medicaid PDL:
    1. Zavzpret (nasal) /Antimigraine Agents, other
    2. Adalimumab-Adaz Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    3. Adalimumab-Adaz Pen Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    4. Adalimumab-Fkjp Kit (injection) /Cytokine and CAM Antagonists
    5. Adalimumab-Fkjp Pen Kit (injection) / Cytokine and CAM Antagonists
    6. Cosentyx Unoready Pen (Subcutane.) / Cytokine and CAM Antagonists
    7. Cyltezo Kit (injection) / Cytokine and CAM Antagonists
    8. Cyltezo Pen Kit (injection) / Cytokine and CAM Antagonists
    9. Hadlima Kit (injection) (CF) 100 mg/ml /  Cytokine and CAM Antagonists
    10. Hadlima Kit (injection) 50 mg/ml / Cytokine and CAM Antagonists
    11. Hadlima Pen Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    12. Hadlima Pen Kit (Injection) 50 mg/ml / Cytokine and CAM Antagonists
    13. Hulio Kit (injection) / Cytokine and CAM Antagonists
    14. Hulio Pen Kit (injection) / Cytokine and CAM Antagonists
    15. Hyrimoz Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    16. Hyrimoz Pen Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    17. Idacio Kit (injection) /Cytokine and CAM Antagonists
    18. Idacio Pen Kit (injection) / Cytokine and CAM Antagonists
    19. Yuflyma Pen Kit (injection) (CF) 100 mg/ml / Cytokine and CAM Antagonists
    20. Yusimry (CF) Pen (subcutaneous) / Cytokine and CAM Antagonists
    21. Altuviiio (intravenous) / Hemophilia Treatment
    22. Roctavian (Intraven) / Hemophilia Treatment
    23. Austedo XR (oral) / Movement Disorders
    24. Austedo XR Titr Pk (oral) / Movement Disorders
    25. Orserdu (oral) / Oncology, oral - Breast
    26. Rezlidhia (oral) / Oncology, oral – Hematologic
    27. aa. Vanflyta (Oral) / Oncology, Oral - Hematologic
    28. bb. Krazati (oral) / Oncology, oral - Lung
    29. cc. Jaypirca (oral) / Oncology, oral - Other
    30. dd. Mekinist Solution (oral) / Oncology, oral - Skin
    31. ee. Tafinlar Suspension (oral) / Oncology, oral - Skin
    32. ff. Orenitram Titration Kit (oral) / PAH Agents, oral and inhaled
    33. gg. Konvomep (oral) / Proton Pump Inhibitors
    34. hh. Zolpidem Capsule (oral) / Sedative Hypnotics
  6. Therapeutic and clinical drug reviews and updates:  Magellan Medicaid Administration
  7. Executive work session
    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  8. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration
  9. Review of action items for next meeting:  January 26, 2024, 9:00 a.m.
  10. Adjourn

The board may take action on any agenda item.

Public Comment: The Health and Human Services Commission (HHSC) welcomes public comments pertaining to topics related to DURB and Medicaid PDL. Members of the public who would like to provide public comment may choose from the following options:

  1. Oral comments provided virtually: Members of the public must pre-register to provide oral comments virtually during the meeting by completing a Public Comment Registration form at https://texashhsmeetings.org/DURB_PCReg_Oct122023 and submitting a completed Public Comment Form, HHS Form 1320 no later than 5:00 p.m. Tuesday, October 10, 2023. Please mark the correct box on the Public Comment Registration form and provide your name, either the organization you are representing or that you are speaking as a private citizen, and your direct phone number. If you have completed the Public Comment Registration form, you will receive an email the day before the meeting with instructions for providing virtual public comment. Public comment is limited to three minutes. Each speaker providing oral public oral comments virtually must ensure their face is visible and their voice audible to the other participants while they are speaking. Each speaker providing oral public comment must state their name and on whose behalf they are speaking (if anyone). If you pre-register to speak and wish to provide a handout before the meeting, please submit an electronic copy in accessible PDF format with a completed Written Public Comment form, HHS Form 1334, that will be distributed by HHS staff to DURB members and State staff. Handouts are limited to two pages (paper size: 8.5” by 11”, one side only). Handouts must be emailed to VDP-Advisory@hhsc.state.tx.us immediately after pre-registering, but no later than 5:00 p.m. Wednesday, October 4, 2023, and include the name of the person who will be commenting. Do not include health or other confidential information in your comments or handouts. Staff will not read aloud handouts aloud during the meeting, but handouts will be provided to DURB members and State staff.
     
  2. Written comments: Members of the public may provide written public comments by completing a Public Comment Registration form,  HHS Form 1334 at https://texashhsmeetings.org/DURB_PCReg_Oct122023. A member of the public who wishes to provide written public comments must email the comments to VDP-Advisory@hhsc.state.tx.us no later than 5:00 p.m. Wednesday, October 4, 2023. Please include your name and the organization you are representing or that you are speaking as a private citizen. Written comments must be emailed to HHSC immediately after pre-registering and include the name of the person who will be commenting. Written comments are limited to ten pages (paper size: 8.5” by 11”, one side only). Do not include health or other confidential information in your comments. Staff will not read written comments aloud during the meeting, but comments will be provided to DURB members and State staff. 
     
  3. Oral comments provided in-person at the meeting location: Members of the public may provide oral public comment during the meeting in person at the meeting location either by pre-registering using the form above or without pre-registering by completing a form at the entrance to the meeting room. Do not include health or other confidential information in your comments.

Note: These procedures may be revised at the discretion of HHSC.

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services, 512-552-7672, and VDP-Advisory@hhsc.state.tx.us.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

Persons who want to attend the meeting and require assistive technology or services should contact Castoreno at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us at least 72 hours before the meeting so appropriate arrangements can be made.